Drugs / autologous bone marrow concentrate
autologous bone marrow concentrate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02538978 | Jan 2017 → Dec 2018 | limb ischemia | Cesca Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03110679 | May → Nov 2016 | osteoarthritis, knee | Rizzoli Orthopaedic Institute | Completed | No outcome recorded |
| Phase 4 | NCT03112122 | Mar 2016 → Dec 2017 | bone marrow disorder | Rizzoli Orthopaedic Institute | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03112122 ↗ |
| Known as | aBMC | “Autologous Bone Marrow Concentrate (aBMC)” NCT02538978 ↗ |
| Known as | BMC | “injections of autologous Bone Marrow Concentrate (BMC)” NCT03112122 ↗ |
| Modality | Cell therapy | “autologous bone marrow cell concentrate (aBMC) into the afflicted lower index limb” NCT02538978 ↗ |
| Route | Intramuscular | “intramuscular injection of autologous bone marrow concentrate (aBMC)” NCT02538978 ↗ |